NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO – Free Report) – Investment analysts at Zacks Small Cap issued their Q1 2024 earnings per share (EPS) estimates for shares of NeuroBo Pharmaceuticals in a report released on Tuesday, April 23rd. Zacks Small Cap analyst D. Bautz anticipates that the company will post earnings per share of ($0.95) for the quarter. The consensus estimate for NeuroBo Pharmaceuticals’ current full-year earnings is ($3.00) per share. Zacks Small Cap also issued estimates for NeuroBo Pharmaceuticals’ Q2 2024 earnings at ($0.95) EPS, Q3 2024 earnings at ($0.97) EPS, Q4 2024 earnings at ($0.97) EPS and FY2026 earnings at ($2.56) EPS.
NeuroBo Pharmaceuticals Stock Up 1.3 %
Shares of NRBO opened at $3.10 on Thursday. The business’s 50-day moving average is $4.43 and its two-hundred day moving average is $3.96. NeuroBo Pharmaceuticals has a fifty-two week low of $2.89 and a fifty-two week high of $6.75.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.
Featured Articles
- Five stocks we like better than NeuroBo Pharmaceuticals
- Technology Stocks Explained: Here’s What to Know About Tech
- 3 Stocks Leading the U.S. Agriculture Comeback
- 3 Small Caps With Big Return Potential
- How to Use Put Debit Spreads to Profit From Falling Stocks
- When to Sell a Stock for Profit or Loss
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for NeuroBo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroBo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.